tbc-11251 has been researched along with Hypertrophy in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cross, DM; Derzi, M; Horsley, E; Owen, K; Stavros, FL | 1 |
| Block, N; Brock, TA; Chen, SJ; Chen, YF; Dixon, RA; Munsch, CL; Sherwood, SJ; Tilton, RG; Wu, C | 1 |
2 other study(ies) available for tbc-11251 and Hypertrophy
| Article | Year |
|---|---|
An overview of the preclinical toxicity and potential carcinogenicity of sitaxentan (Thelin®), a potent endothelin receptor antagonist developed for pulmonary arterial hypertension.
Topics: Alkaline Phosphatase; Animals; Antihypertensive Agents; Blood Coagulation; Carcinogenicity Tests; Carcinogens; Chemical and Drug Induced Liver Injury, Chronic; Dogs; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Endothelin Receptor Antagonists; Erythrocyte Indices; Female; Hypertension, Pulmonary; Hypertrophy; Isoxazoles; Liver; Liver Function Tests; Male; Mice; Mice, Inbred Strains; Organ Size; Rats; Rats, Sprague-Dawley; Risk Assessment; Species Specificity; Thiophenes | 2012 |
Attenuation of pulmonary vascular hypertension and cardiac hypertrophy with sitaxsentan sodium, an orally active ET(A) receptor antagonist.
Topics: Animals; Cardiomegaly; Disease Models, Animal; Endothelin Receptor Antagonists; Endothelin-1; Hypertension, Pulmonary; Hypertrophy; Hypoxia; Isoxazoles; Male; Monocrotaline; Oxygen; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; Thiophenes; Vasoconstriction; Weight Gain | 2000 |